Provided by Tiger Trade Technology Pte. Ltd.

Biomea Fusion, Inc.

1.32
+0.07005.60%
Post-market: 1.340.0200+1.52%17:46 EDT
Volume:834.94K
Turnover:1.09M
Market Cap:95.44M
PE:-2.80
High:1.34
Open:1.27
Low:1.25
Close:1.25
52wk High:2.24
52wk Low:0.8719
Shares:72.30M
Float Shares:67.01M
Volume Ratio:0.80
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4711
EPS(LYR):-1.1832
ROE:-164.14%
ROA:-63.46%
PB:7.86
PE(LYR):-1.12

Loading ...

Vaxart Q2 Revenue Falls on Lower Government Contract Income

Reuters
·
Aug 07

Biomea Fusion price target lowered to $7 from $9 at Citizens

TIPRANKS
·
Aug 07

Biomea Fusion (BMEA) Gets a Buy from Oppenheimer

TIPRANKS
·
Aug 06

PepGen Q2 Net Loss Narrows as Expenses Fall

Reuters
·
Aug 06

Amylyx Pharmaceuticals Q2 Posts Higher than Expected Loss

Reuters
·
Aug 06

Analyst Maintains Buy Rating on Biomea Fusion as Metabolic Pipeline Advances and $4 Price Target Remains Unchanged

TIPRANKS
·
Aug 06

Biomea Fusion, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Biomea Fusion Q2 EPS $(0.12) Beats $(0.22) Estimate

Benzinga Earnings
·
Aug 06

Biomea Fusion reports Q2 EPS (12c), consensus (23c)

TIPRANKS
·
Aug 06

Biomea Fusion Q2 Loss Narrows, Cash Runway into Q2 2027

Reuters
·
Aug 06

Biomea Fusion Q2 Net Loss Narrows to $8.33 Million; R&D Expenses Fall 44.68% to $9.14 Million

Reuters
·
Aug 06

Biomea Fusion Q2 Basic EPS USD -0.12

THOMSON REUTERS
·
Aug 06

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

GlobeNewswire
·
Aug 06

Biomea Fusion Inc Expected to Post a Loss of 22 Cents a Share - Earnings Preview

Reuters
·
Aug 01

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Jul 31

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Biomea Fusion (BMEA) and Senseonics Holdings (SENS)

TIPRANKS
·
Jun 24

Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Novavax (NVAX)

TIPRANKS
·
Jun 12

Biomea Fusion shareholders elect two directors at annual meeting

Reuters
·
Jun 11

Biomea Labs: Buy Rating Reiterated as Icovamenib Data Strengthen Metabolic Disease Thesis; $4 Price Target Maintained

TIPRANKS
·
Jun 08

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“Ada”) 86TH Scientific Sessions and Announces Expansion of Ongoing Phase I Bmf-650 Study

THOMSON REUTERS
·
Jun 06